Its ability to induce over 17-fold increase in β-cell proliferation in response to insulin resistance suggested that betatrophin can be used to augment other T2D treatments and reduce dependency on insulin injections [5,6,7]. The gene discussed is ANGPTL8; the disease is Insulin resistance.